US 12,076,322 B2
Compounds and methods for kinase modulation, and indications therefor
Prabha N. Ibrahim, Mountain View, CA (US); Chao Zhang, Moraga, CA (US); Wayne Spevak, Berkeley, CA (US); Jiazhong Zhang, Foster City, CA (US); Guoxian Wu, Foster City, CA (US); Jack Lin, Hercules, CA (US); Hanna Cho, Oakland, CA (US); Marika Nespi, Berkeley, CA (US); Songyuan Shi, Fremont, CA (US); Todd Ewing, Walnut Creek, CA (US); and Ying Zhang, Fremont, CA (US)
Assigned to Plexxikon Inc., South San Francisco, CA (US)
Filed by Plexxikon Inc., South San Francisco, CA (US)
Filed on Aug. 25, 2022, as Appl. No. 17/895,972.
Application 15/435,569 is a division of application No. 13/820,734, granted, now 9,624,213, previously published as PCT/US2012/023543, filed on Feb. 1, 2012.
Application 17/895,972 is a continuation of application No. 17/722,229, filed on Apr. 15, 2022, abandoned.
Application 17/722,229 is a continuation of application No. 15/435,569, filed on Feb. 17, 2017, granted, now 11,337,976.
Claims priority of provisional application 61/440,339, filed on Feb. 7, 2011.
Prior Publication US 2023/0277534 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/506 (2006.01); A61K 31/437 (2006.01); A61K 31/5377 (2006.01); C07D 471/04 (2006.01)
CPC A61K 31/506 (2013.01) [A61K 31/437 (2013.01); A61K 31/5377 (2013.01); C07D 471/04 (2013.01)] 7 Claims
 
1. A method for treating a subject with a B-Raf mediated disease or condition, said method comprising administering to said subject an effective amount of a compound of formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
each R11 is independently halogen;
Q is H or F; and
m is 0, 1, or 2;
wherein the B-Raf mediated disease or condition is glioma.